scholarly journals Prostate-specific antigen immunoreactivity in women with breast cancer

1996 ◽  
Vol 42 (10) ◽  
pp. 1721-1722 ◽  
Author(s):  
L Dibbelt ◽  
G Vierke ◽  
W Wunsche
Keyword(s):  
Breast Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen

THE ACCURACY AND EFFECTIVENESS OF ROUTINE POPULATION SCREENING WITH MAMMOGRAPHY, PROSTATE-SPECIFIC ANTIGEN, AND PRENATAL ULTRASOUND

2001 ◽  
Vol 17 (3) ◽  
pp. 275-304 ◽  
Author(s):  
Steven H. Woolf
Keyword(s):  
Breast Cancer ◽  
Prostate Specific Antigen ◽  
False Positive ◽  
Congenital Anomalies ◽  
Specific Antigen ◽  
Prenatal Ultrasound ◽  
Screening Tests ◽  
Published Data ◽  
Psa Screening ◽  
Abnormal Results

Objective: To review published data regarding the accuracy and effectiveness of three screening tests: mammography, prostate-specific antigen (PSA), and prenatal ultrasound.Methods: Published evidence regarding the accuracy and effectiveness of the three tests was collected by computerized literature search and supplemented by manual review of relevant bibliographies.Results: Screening mammograms lower breast cancer mortality by about 20%. Most data come from women aged 50–64 years; women aged 40–49 years may also benefit, but the absolute risk reduction is lower. Up to 1,500 to 2,500 women must undergo screening to prevent one death from breast cancer. Mammograms miss approximately 12% to 37% of cancers, generate false-positive results, and cause anxiety while abnormal results are evaluated. PSA screening can detect 80% to 85% of prostate cancers but has a high false-positive rate. There is little direct evidence that early detection reduces morbidity or mortality. Indirect evidence includes a trend toward earlier stage tumors and steadily declining mortality rates in geographic areas where PSA screening has become common. Potential harms include the morbidity associated with evaluating abnormal results, and complications from treatment (e.g., impotence, incontinence). The overall balance of benefits and harms remains uncertain in the absence of better evidence. Prenatal ultrasound may reduce perinatal mortality, primarily through elective abortions for congenital anomalies, but does not appear to lower live birth rates. Although ultrasound has no proven effect on neonatal morbidity, it provides more accurate estimates of gestational age that prevent unnecessary inductions for post-term pregnancy. Screening detects multiple gestations, congenital anomalies, and intrauterine growth retardation, but direct health benefits from having this knowledge are unproved. Ultrasound has both positive and negative psychological effects on parents. The scans do not appear to harm childhood development.Conclusions: Even for the most established screening tests, the appropriateness of routine testing depends on subjective value judgments about the quality of supporting evidence and about the trade-offs between benefits and harms. Individuals, clinicians, policy makers, and governments must weigh the evidence in light of these values and the constraints imposed by available resources.

Interaction between estrogens and androgen receptor genes microsatellites, prostate-specific antigen and androgen receptor expressions in breast cancer

Neoplasma ◽  
2010 ◽  
Vol 57 (3) ◽  
pp. 198-206 ◽  
Author(s):  
D. Narita ◽  
A. Anghel ◽  
A. Cimpean ◽  
D. Izvernariu ◽  
N. Cireap ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Prostate Specific Antigen ◽  
Specific Antigen

Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer

2002 ◽  
Vol 26 (2) ◽  
pp. 149-157 ◽  
Author(s):  
Edward R. Sauter ◽  
Inna Chervoneva ◽  
Anastasia Diamandis ◽  
Javad M. Khosravi ◽  
Samuel Litwin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Prostate Specific Antigen ◽  
Binding Protein ◽  
Specific Antigen ◽  
Nipple Aspirate Fluid ◽  
Insulin Like Growth Factor ◽  
Factor Binding

The significance of prostate specific antigen (PSA) in breast cancer

1998 ◽  
Vol 34 ◽  
pp. S106-S107
Author(s):  
J.G.M. Klijn ◽  
E.P. Diamandis ◽  
H. Yu ◽  
M.P. Look ◽  
M.E. Meijer-van Gelder ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen

scholarly journals Prostate-specific antigen in serum of women with breast cancer

1995 ◽  
Vol 72 (3) ◽  
pp. 728-731 ◽  
Author(s):  
M Giai ◽  
H Yu ◽  
R Roagna ◽  
R Ponzone ◽  
D Katsaros ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen

scholarly journals CLINICAL SIGNIFICANSE OF PROSTATE-SPECIFIC ANTIGEN IN BREAST CANCER PATIENTS

2020 ◽  
Vol 19 (6) ◽  
pp. 28-37
Author(s):  
N. S. Sergeeva ◽  
T. A. Karmakova ◽  
I. I. Alentov ◽  
A. D. Zikiryahodzhaev ◽  
D. R. Ortabaeva ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Specific Antigen ◽  
Clinical Significance ◽  
Molecular Subtype ◽  
Specific Antigen ◽  
Elevated Serum ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Early Stages

Background. Prostate-specific antigen (PSA ) is predominantly produced by prostate epithelium, however, other tissues can serve as its minor sources in both men and women, including breast tissue. In women, elevated serum PSA levels have been described in different physiological and pathological conditions, including benign breast diseases and breast cancer (BC). PSA is considered as a potential serum tumor marker for BC, but evidences of its possible clinical significance are insufficiently convincing.Aim of the study: investigation of PSA levels in female BC patients and assessment of perspectives of its study as a diagnostic tool for early detection of BC.Material and methods. Serum PSA levels were measured by chemiluminescence immunoassay (ARCHITECT , Abbott) in 99 female patients with histologically confirmed BC (carcinoma in situ – 11, stage I – 56, stage IIA – 32) and 25 conditionally healthy female donors.Results. In the donor group, serum PSA was revealed in 22/25 (88,0 %) cases, and its mean level was 4.0 ± 0.9 ng/l. In the group of BC patients, detectable PSA level was revealed in 68/99 (68.7 %) cases, and its mean level was 2.8 ± 0.9 ng/l. Differences between groups of BC patients and donors in mean marker values were not statistically significant (p>0,05). Serum PSA levels were higher in young women: in the group of BC patients under 40 years old, percentage of PSA -positive cases was 89 %, in the group of patients over 50 years old – 60 %; in groups of donors under 40 and over 50 years old – 100 % and 80 %, respectively. In cases of in situ carcinoma, the mean serum PSA was higher than in cases with stages I and II (3.0 ± 1.2 ng/l vs 1.9 ± 0.3 ng/l and 1.6 ± 0.3 ng/l, respectively; p>0,05). In the group of BC patients, no PSA levels were found to be dependent on the histological type, grade and molecular subtype of the tumor.Conclusion. The PSA level has no clinical significance in early stages of BC, since the proportion of cases with elevated PSA levels and it’s mean value in patients with early stages of BC don’t differ from those in the group of healthy women. 

Sign in / Sign up

Export Citation Format

Share Document